Halozyme Therapeutics Reports Third Quarter 2011 Financial Results – PR Newswire (press release)

Halozyme Therapeutics Reports Third Quarter 2011 Financial Results
PR Newswire (press release)
Baxter presented its Phase III data for the HyQ program at the American College of Allergy, Asthma & Immunology. HyQ was shown to be effective in subjects with Primary Immunodeficiency and enabled 94% of subjects to receive full 3 or 4-weekly doses of
Baxter Presents Phase III HyQ Efficacy and Tolerability Data at American MarketWatch (press release)

all 27 news articles »

View full post on asthma – Google News

Palatin Technologies, Inc. Reports Third Quarter Fiscal Year 2011 Results – PR Newswire (press release)

Palatin Technologies, Inc. Reports Third Quarter Fiscal Year 2011 Results
PR Newswire (press release)
Palatin has started discussions with a number of potential development and marketing partners for PL-3994 for acute asthma, which would include the proof-of-concept human trial for asthma using a subcutaneously administered formulation and development
Palatin Technologies CEO Discusses F3Q2011 Results – Earnings Call TranscriptSeeking Alpha

all 20 news articles »

View full post on asthma – Google News